Review of the safety and feasibility of rapid infusion of rituximab

Journal of Oncology Practice

Volumn 6, Issue 2, 2010, Pages 91-93

  Atmar, Jill ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT RESPIRATORY DISTRESS SYNDROME; ANGIONEUROTIC EDEMA; ASTHENIA; B CELL LYMPHOMA; CARDIOGENIC SHOCK; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG INFUSION; DRUG SAFETY; DYSPNEA; FEASIBILITY STUDY; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; HYPOTHERMIA; HYPOXIA; LUNG INFILTRATE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PREMEDICATION; PROGRESSION FREE SURVIVAL; RASH; REVIEW; RIGOR; SORE THROAT; THORAX PAIN; TREATMENT OUTCOME; URTICARIA;

EID: 77956595001     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.200001     Document Type: Review

References (25)

1. Rastetter W, Molina A: Rituximab: Expanding role in therapy for lymphomas and autoimmune disorders. Annu Rev Med 55:477-503, 2004
2. Molina A: A decade of rituximab: Improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 59:237-250, 2008
3. Hallek M, Fingerle-Rowson G, Fink A-M, et al: Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 112, 2008 (abstr 325)
4. Robak T, Moiseev SI, Dmoszynska A, et al: Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: Final results from the international randomized Phase III REACH trial. Blood 112, 2008 (abstr LBA-1)
5. Chung CH: Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13:725-732, 2008
6. Sehn LH, Donaldson J, Filewich A, et al: Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 109: 4171-4173, 2007
7. Genentech Inc: Rituxan [package insert] South San Francisco, CA, Genentech Inc, 2008. http://www.gene.com/gene/products/information/pdf/ rituxanprescribing.pdf
8. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
9. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105: 1417-1423, 2005
10. Association of Community Cancer Centers: Oncology Newsfeed: ACCC analysis - Final 2009 OPPS rule, payment for some chemo administration services increases, others decline. http://accc-cancer.org/mediaroom/media-newsfeed.asp
11. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153-2164, 2001
12. Aurran-Schleinitz T, Gravis G, Vittot M, et al: One hour rituximab infusion is safe and improves patient care and outpatient unit management. Blood 106, 2005 (abstr 4759)
13. Provencio M, Cerdeira S, Bonilla F, et al: Rapid-infusion rituximab in lymphoma treatment. Ann Oncol 17:1027-1028, 2006
14. Siano M, Lerch E, Zucca E, et al: A phase I-II study to determine the maximum tolerated infusion-rate of rituximab, with a special emphasis on monitoring the effect of rituximab on cardiac function. Clin Cancer Res 14:7935-7939, 2008
15. Tuthill M, Crook T, Corbet T, et al: Rapid infusion of rituximab over 60 min. Eur J Haematol 82:322-325, 2009
16. Middleton H, Mollee P, Bird R, et al: Accelerated delivery of rituximab is safe on an out-patient basis. Blood 106, 2005 (abstr 4777)
17. Salar A, Casao D, Cervera M, et al: Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution. Eur J Haematol 77:338-340, 2006
18. Milone J, Prates V, Zoppegno L, et al: Rapid infusion of rituximab (RIR) is well tolerated and can safely be delivered in patients with lymphoproliferative diseases. Blood 110, 2007 (abstr 4503)
19. Corey P, Go R, Schaper A: A nurse can safely deliver rituximab over 90 minutes. Oncology Nursing Society 32nd Annual Congress. April 24-27, 2007, Las Vegas, NV (abstr 2010)
20. Gibbs S, Pout G, Wimperis J: Rapid infusion rituximab is as clinically effective and safe as conventional infusion regimes in the treatment of diffuse large B-cell lymphoma: A 2-year prospective study. Haematologica 92, 2007 (suppl 2; abstr 0708)
21. Al Zahrani A, Ibrahim N, Al Eid A. Rapid infusion rituximab changing practice for patient care. J Oncol Pharm Pract 15:183-186, 2009
22. Pfreundschuh M, Trumper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
23. Provencio M, Sanchez A, Mendez M et al: A prospective study of cardiotoxicity in non-Hodgkin lymphoma patients with rapid infusion rituximab. Blood 112, 2008 (abstr 4966)
24. Witzens-Harig M, van Hazel G, Chamone DFA, et al: Safety and efficacy in patients receiving maintenance rituximab for follicular lymphoma: Early results from Phase IIIb MAXIMA trial. Blood 114, 2009 (suppl; abstr 3756)
25. US National Institutes of Health, ClinicalTrials.gov: A study of rituximab alternative dosing rate in patients with previously untreated diffuse large B-cell or follicular non-Hodgkin's lymphoma (RATE). http://www. clinicaltrials.gov/ct2/show/NCT00719472?term=RATE&rank=4